Heart failure & cardiomyopathies
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial
Primary result · Sustained ≥50% eGFR decline or kidney failureResult — go to the resultHazard ratio 1.33 95% CI 0.94–1.89Authors' conclusion
In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes.
Study context
- Population
- Patients with HF with mildly reduced or preserved EF
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Sustained ≥50% estimated glomerular filtration rate (eGFR) decline or kidney failure (sustained eGFR <15 mL/min/1.73 m², maintenance dialysis, renal transplantation)
- Follow-up
- Median 2.6 years
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
Sustained ≥50% eGFR decline or kidney failure · median 2.6 years
Hazard ratio
1.33
95% CI 0.94–1.89
Events by treatment group
Finerenone
75
events
Placebo
55
events
Finerenonevs Placebo
HR 1.33 (95% CI 0.94–1.89)
As reported in the abstract
Secondary outcomes
| Outcome | Difference (mL/min/1.73 m²) (95% CI) | |
|---|---|---|
| Acute eGFR decline · first 3 months | −2.9 (−3.4 to −2.4) | |
| −4−202Difference, mL/min/1.73 m² (linear scale) |
| Outcome | Difference (mL/min/1.73 m² per year) (95% CI) | |
|---|---|---|
| Total eGFR slope | −0.7 (−0.9 to −0.4) | |
| −1−0.500.5Difference, mL/min/1.73 m² per year (linear scale) |
| Outcome | HR (95% CI) | |
|---|---|---|
| New-onset microalbuminuria and macroalbuminuriaFinerenonevs PlaceboMicroalbuminuria (24% risk reduction) | 0.76 (0.68–0.83) | |
| New-onset microalbuminuria and macroalbuminuriaFinerenonevs PlaceboMacroalbuminuria (38% risk reduction) | 0.62 (0.53–0.73) | |
| 0.512Hazard ratio (log scale) |
| Outcome | Estimate |
|---|---|
| Chronic eGFR slope (from 3 months)Not altered | difference +0.2 mL/min/1.73 m² per year (95% CI −0.1 to 0.4) |
| UACR reduction · over 6 monthsPersisted throughout follow-up | reduction 30% (95% CI 25%–34%) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. Published 25 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →